Cyclopharm Limited
ASX CYC.AX
Cyclopharm Limited Net Income Margin for the year ending December 31, 2023: -17.32%
-
Cyclopharm Limited Net Income Margin for the year ending December 31, 2022 was -28.47%, a -0.02% change year over year.
-
Cyclopharm Limited Net Income Margin for the year ending December 31, 2021 was -28.47%, a 30.87% change year over year.
-
Cyclopharm Limited Net Income Margin for the year ending December 31, 2020 was -41.18%, a -99.06% change year over year.
-
Cyclopharm Limited Net Income Margin for the year ending December 31, 2019 was -20.69%, a -7,720.66% change year over year.
| Date | Net Income Margin | EBITDA Margin | EBIT Margin | EBITDA |
|---|
| CEO | Mr. James S. McBrayer AIM, BSPharm, F.A.C.I.D., FAICD, GDM |
| IPO Date | Jan. 17, 2007 |
| Location | Australia |
| Headquarters | 1 The Crescent |
| Employees | 87 |
| Sector | Health Care |
| Industries | |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Past 5 years
USD 0.68
StockViz Staff
January 16, 2025
Any question? Send us an email